Nxera’s Focused Restructuring to Enhance Path to Profit
Nxera Pharma will streamline its operations and refocus R&D around de-risked GPCR biology, cutting approximately 15% of its workforce...
James M. O’Brien Appointed as Mesoblast Chief Financial Officer
Mesoblast has appointed James M. O’Brien as its US-based chief financial officer as the company transitions to a fully...
Fennec Pharmaceuticals Q3 2025 Financial Results Update
Fennec Pharmaceuticals reported record third-quarter 2025 net product sales of $12.5 million for Pedmark, up 79% year over year,...
Predictive Oncology Q3 Results & New Digital Asset Strategy
Predictive Oncology has launched an aggressive pivot into decentralized AI infrastructure alongside reporting weak third-quarter financials. The company initiated...
Benitec Biopharma Releases Q1 2026 Financials, Ops Update
Benitec Biopharma has secured FDA Fast Track designation for BB-301 and reported positive interim results from its Phase 1b/2a...
HCW Biologics Reports Third Quarter 2025 Financial Results
HCW Biologics reported third-quarter 2025 results and outlined near-term clinical milestones, including plans to dose the first patient in...
Mesoblast Appoints James M. O’Brien Chief Financial Officer
Mesoblast has appointed James M. O’Brien as its US-based chief financial officer, aligning the company’s finance leadership with its...
Verrica Pharmaceuticals Reports Q3 2025 Financial Results
Verrica Pharmaceuticals reported third-quarter 2025 revenue of $14.3 million, driven by $3.6 million in Ycanth sales and $10.7 million...
Biogen Completes Acquisition of Alcyone Therapeutics
Biogen has completed its acquisition of Alcyone Therapeutics, adding an implantable intrathecal drug delivery system, ThecaFlex DRx, to its...
Entera Bio Announces Q3 2025 Financial Results & Updates
Entera Bio secured FDA alignment that a single, 24‑month, multinational Phase 3 trial using change in total hip bone...